{"id":837,"date":"2021-09-26T02:12:00","date_gmt":"2021-09-26T02:12:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3519131_CN19131_0"},"modified":"2021-09-26T02:12:00","modified_gmt":"2021-09-26T02:12:00","slug":"boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=837","title":{"rendered":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit"},"content":{"rendered":"

Sept. 26, 2021<\/span>, BOSTON<\/span> \/PRNewswire\/ — Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA\/CD3 bispecific antibody at World Bispecific Summit 2021. <\/p>\n

The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the 12th<\/sup> time this year. It has become a prestigious platform in the industry for academic exchanges. The upcoming event will take place online from September 29 to October 1, 2021<\/span> Eastern Standard Time.<\/p>\n

Details of the oral presentation by Boan Biotech are as follows:<\/b><\/p>\n

Title:<\/b> Optimization of CD3+ T-cell Engager to Improve Safety Profile
Session: <\/b>T-cell Based Approaches for Oncology Therapeutics
Time<\/b>: October 1, 2021<\/span><\/p>\n

Background<\/b><\/p>\n

CD3+ T-cell engagers are a group of the most promising bispecific antibodies for the treatment of cancers. But they face major challenges including the dose-limiting, life threatening cytokine release syndrome (CRS) toxicity, suboptimal potency, and the on-target off-tumor toxicity. To overcome those challenges, Boan Biotech developed an optimized platform for CD3+ bispecific T-cell engagers with a unique combination of high potency, reduced cytokine release and tumor-targeting selectivity.  <\/p>\n

The CEA\/ CD3 bispecific antibody BA1202 is the first clinical candidate developed on the leading bispecific T-cell Engager platform. The pre-clinical research data of BA1202 showed a high potency in killing cancer cells, significantly reduced cytokine release, and superior efficacy. <\/p>\n

In addition to BA1202, multiple bispecific antibody candidates with similar optimized format and the reduced CD3 affinity have been validated both in vitro<\/i> and in vivo<\/i> to have a similar advantage against different solid tumor targets. Boan Biotech plans to speed up the effort to take these bispecific T-cell engagers as investigational drugs to clinical trials, to address the huge unmet needs in treating patients with late-stage cancers.<\/p>\n

About Boan Biotech<\/u><\/b><\/p>\n

As a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech’s antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. The company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 8 biosimilar product candidates, one of which \u2013 Boyounuo (Bevacizumab Injection) \u2013 has been launched in China<\/span>.<\/p>\n

Boan Biotech has expertise in the full industry chain: antibody generation, lead optimization, cell line development, process development, technology transfer, pilot and commercial scale production. The company is also actively exploring other cutting-edge technologies. Its cell therapy products use non-viral vectors for CAR-T for late stage solid tumors. In addition, Boan Biotech is exploring novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients. Outside of China<\/span>, Boan Biotech also pursues biopharmaceutical products development in the US and EU markets.<\/p>\n

\"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-ceacd3-bispecific-antibody-at-world-bispecific-summit-301385115.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sept. 26, 2021, BOSTON \/PRNewswire\/ — Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA\/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the […]<\/p>\n","protected":false},"author":8,"featured_media":838,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"\nBoan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=837\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit - My Blog\" \/>\n<meta property=\"og:description\" content=\"Sept. 26, 2021, BOSTON \/PRNewswire\/ — Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA\/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=837\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-26T02:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/09\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png\" \/>\n\t<meta property=\"og:image:width\" content=\"16\" \/>\n\t<meta property=\"og:image:height\" content=\"16\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\\\/CD3 Bispecific Antibody at World Bispecific Summit\",\"datePublished\":\"2021-09-26T02:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837\",\"name\":\"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\\\/CD3 Bispecific Antibody at World Bispecific Summit - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png\",\"datePublished\":\"2021-09-26T02:12:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png\",\"width\":16,\"height\":16},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=837#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\\\/CD3 Bispecific Antibody at World Bispecific Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=837","og_locale":"en_US","og_type":"article","og_title":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit - My Blog","og_description":"Sept. 26, 2021, BOSTON \/PRNewswire\/ — Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA\/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the […]","og_url":"https:\/\/transmediavictoria.net.au\/?p=837","og_site_name":"My Blog","article_published_time":"2021-09-26T02:12:00+00:00","og_image":[{"width":16,"height":16,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/09\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=837#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=837"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit","datePublished":"2021-09-26T02:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=837"},"wordCount":507,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=837#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/09\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=837","url":"https:\/\/transmediavictoria.net.au\/?p=837","name":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=837#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=837#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/09\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png","datePublished":"2021-09-26T02:12:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=837#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=837"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=837#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/09\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/09\/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-cea-cd3-bispecific-antibody-at-world-bispecific-summit.png","width":16,"height":16},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=837#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=837"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/838"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}